| Primary |
| Computerised Tomogram |
29.4% |
| Hypertension |
9.9% |
| Arteriogram Coronary |
7.7% |
| Angiogram |
6.3% |
| Prophylaxis |
6.3% |
| Angina Pectoris |
4.5% |
| Diagnostic Procedure |
4.5% |
| Computerised Tomogram Abdomen |
3.4% |
| Percutaneous Coronary Intervention |
3.4% |
| Musculoskeletal Pain |
3.2% |
| Product Used For Unknown Indication |
3.0% |
| Balloon-occluded Retrograde Transvenous Obliteration |
2.8% |
| Spinal Myelogram |
2.6% |
| Catheterisation Cardiac |
2.0% |
| Computerised Tomogram Thorax |
2.0% |
| Diabetes Mellitus |
2.0% |
| Hypercholesterolaemia |
1.8% |
| Thrombosis Prophylaxis |
1.8% |
| Aortic Dissection |
1.6% |
| Arteriosclerosis Obliterans |
1.6% |
|
| Anaphylactic Shock |
12.9% |
| Vomiting |
9.3% |
| Shock |
8.6% |
| Nephropathy Toxic |
6.4% |
| Urticaria |
5.7% |
| Anaphylactic Reaction |
5.0% |
| Central Nervous System Lesion |
4.3% |
| Respiratory Arrest |
4.3% |
| Toxic Skin Eruption |
4.3% |
| Anaphylactoid Reaction |
3.6% |
| Angioedema |
3.6% |
| Blood Creatinine Increased |
3.6% |
| Contrast Media Allergy |
3.6% |
| Dyspnoea |
3.6% |
| Hypersensitivity |
3.6% |
| Hypertensive Crisis |
3.6% |
| Loss Of Consciousness |
3.6% |
| Nausea |
3.6% |
| Pyrexia |
3.6% |
| Renal Failure Acute |
3.6% |
|
| Secondary |
| Drug Use For Unknown Indication |
17.1% |
| Computerised Tomogram |
16.1% |
| Hypertension |
8.3% |
| Product Used For Unknown Indication |
6.8% |
| Percutaneous Coronary Intervention |
5.4% |
| Prophylaxis |
5.3% |
| Musculoskeletal Pain |
5.2% |
| Acute Myocardial Infarction |
4.5% |
| Arteriogram Coronary |
4.2% |
| Angina Pectoris |
4.1% |
| Angiogram |
3.1% |
| Diabetes Mellitus |
3.0% |
| Myocardial Infarction |
2.4% |
| Colon Cancer |
2.3% |
| Metastases To Liver |
2.3% |
| Diagnostic Procedure |
2.2% |
| Thrombosis Prophylaxis |
2.2% |
| Gastric Ulcer |
2.0% |
| Computerised Tomogram Abdomen |
1.8% |
| Hypercholesterolaemia |
1.8% |
|
| Anaphylactic Shock |
20.8% |
| Shock |
7.4% |
| Renal Impairment |
6.7% |
| Respiratory Arrest |
6.7% |
| Nephropathy Toxic |
6.0% |
| Toxic Skin Eruption |
6.0% |
| Pyrexia |
4.7% |
| Renal Failure Acute |
4.7% |
| Contrast Media Allergy |
4.0% |
| Acute Generalised Exanthematous Pustulosis |
3.4% |
| Anaphylactoid Reaction |
3.4% |
| Cardio-respiratory Arrest |
3.4% |
| Convulsion |
3.4% |
| Vomiting |
3.4% |
| Altered State Of Consciousness |
2.7% |
| Embolism Arterial |
2.7% |
| Eosinophil Count Increased |
2.7% |
| Paraplegia |
2.7% |
| Psoriasis |
2.7% |
| Pustular Psoriasis |
2.7% |
|
| Concomitant |
| Hypertension |
20.1% |
| Product Used For Unknown Indication |
7.7% |
| Diabetes Mellitus |
7.4% |
| Angina Pectoris |
5.8% |
| Computerised Tomogram |
5.8% |
| Angiogram |
5.5% |
| Prophylaxis |
5.5% |
| Rash |
5.2% |
| Constipation |
4.3% |
| Drug Use For Unknown Indication |
4.0% |
| Coronary Artery Bypass |
3.5% |
| Gastritis Prophylaxis |
3.4% |
| Percutaneous Coronary Intervention |
3.2% |
| Hypercholesterolaemia |
3.1% |
| Insomnia |
2.9% |
| Arteriosclerosis Obliterans |
2.8% |
| Pain |
2.8% |
| Hepatic Neoplasm Malignant |
2.5% |
| Nuclear Magnetic Resonance Imaging |
2.3% |
| Catheterisation Cardiac |
2.2% |
|
| Liver Function Test Abnormal |
16.2% |
| Ventricular Extrasystoles |
9.5% |
| Pain |
8.1% |
| Cytogenetic Abnormality |
6.8% |
| In-stent Coronary Artery Restenosis |
5.4% |
| Rhabdomyolysis |
5.4% |
| Unevaluable Event |
5.4% |
| Anaphylactic Shock |
4.1% |
| Liver Disorder |
4.1% |
| Pharyngeal Erythema |
4.1% |
| Pruritus |
4.1% |
| Stevens-johnson Syndrome |
4.1% |
| Toxic Skin Eruption |
4.1% |
| Altered State Of Consciousness |
2.7% |
| Anaphylactoid Shock |
2.7% |
| Anxiety |
2.7% |
| Arteriosclerosis Obliterans |
2.7% |
| Chronic Hepatic Failure |
2.7% |
| Condition Aggravated |
2.7% |
| Disseminated Intravascular Coagulation |
2.7% |
|
